▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

BostonGene to Present Omnimodal Foundation AI for Cancer and the Immune System at SITC 2025 Annual Meeting

BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 4...

Immagine

BostonGene approach advances biomarker discovery, predicts immune response and toxicity and reveals resistance mechanisms across cancer types

WALTHAM, Mass.: BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland. BostonGene will also exhibit at booth 319.

BostonGene will highlight research demonstrating the power of its omnimodal foundation AI to advance precision oncology. The studies showcase innovative approaches for identifying predictive biomarkers, optimizing patient selection in clinical trials, forecasting treatment-related toxicities through blood-based profiling and assessing the impact of combination therapies in B-cell non-Hodgkin lymphoma.

Scientific poster presentations details are below:

Friday, November 7

Abstract: 153
Title: Association of candidate tertiary lymphoid structures in baseline tumor tissue with response to ipilimumab in patients with metastatic castration-resistant prostate cancer (mCRPC)

Saturday, November 8

Abstract: 154
Title: Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy

Abstract: 504
Title: Biological Mechanisms of Resistance to Macrophage Checkpoint Inhibitors in Relapsed B-cell Non-Hodgkin Lymphoma

Abstract: 1094
Title: Pre-treatment predictive modeling of immune-related adverse event risk in immune checkpoint blockade therapy: A multi-modal machine learning approach from a real-world setting (RADIOHEAD Cohort Study)

Abstracts will be published on November 4 in the Journal for ImmunoTherapy of Cancer (JITC), SITC’s official journal. To learn more or to schedule a meeting with BostonGene during SITC, please contact Hannah Oman at events@bostongene.com.

About BostonGene Corporation
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Arkose Labs Report Exposes Evolving Cybercriminal Tactics Including Agentic…

#bot--Arkose Labs, the leading fraud prevention, device ID and bot management company, has published "Enterprises Under Attack: Quarterly Threat Actor…

Validation of FDA-Regulated Systems Used in Drug Development & Submissions…

The "Validation of FDA-Regulated Systems Used in Drug Development & Submissions Using Artificial Intelligence (AI), Machine Learning (ML) & Large…

26th UN Tourism General Assembly kicks off in Riyadh

The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and…

OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”

OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!